Can Hormone Receptor or HER2 Status Change When Breast Cancer Recurs and Metastasizes?

Breast cancer is the most common cancer in women worldwide and in our country; in 2018, approximately 2 million 100 thousand new cases were diagnosed worldwide. At diagnosis, approximately %10 of patients are at the metastatic (4th) stage. Early and locally advanced stagesare the stages at which other patients are diagnosed and treated; approximately %30 of these later experience metastasis or cancer recurrence in the same region. Treatment of metastatic disease depends on hormone and HER2 receptor status. Whether these receptors are positive or negative changes treatment completely. When a patient initially diagnosed at an early stage later experiences recurrence and/or metastasis, these receptors, which are breast cancer biomarkers , may also change, as demonstrated in many previous studies.
Scientific data show that this discordance (change) ranges from %12 – 35 for estrogen receptors (ER), %30 – 60 for progesterone receptors (PR), and for HER2 receptors, %5 – 15. A recent study on this topic came from India, a developing country.

This study, published in the Journal of Global Oncology, included patients initially diagnosed with stage I, II or III breast cancer who received adjuvant treatment and follow-up, of whom 103 developed metastasis. Biopsies were taken from their metastatic or recurrent sites. Changes between receptor status in initial pathology and the latest pathology were examined.
According to the study results;
- for ER, %21.3,
- for PR, %29.1 and
- for HER-2, %15.5 discordance (change) occurred.
Conversion from initially negative to positive in the metastatic setting occurred at these rates;
- for ER, %13.6,
- for PR, %11.7,
- for HER-2, %8.7.
What does this study show us?
Like earlier studies on this subject, this study showed that initial biomarker status may change in %15 – 25 of cases when a tumor becomes metastatic. These biomarkers, which are crucial to treatment decisions, should therefore be updated in the metastatic setting through new biopsies to determine whether there has been a change, and new treatment decisions should be made accordingly.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.